EA200300040A1 - 1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторов - Google Patents
1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторовInfo
- Publication number
- EA200300040A1 EA200300040A1 EA200300040A EA200300040A EA200300040A1 EA 200300040 A1 EA200300040 A1 EA 200300040A1 EA 200300040 A EA200300040 A EA 200300040A EA 200300040 A EA200300040 A EA 200300040A EA 200300040 A1 EA200300040 A1 EA 200300040A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antagonists
- nicotinic receptors
- neuronal nicotinic
- cyclohexanes
- aminoalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Определенные 1-аминоалкилциклогексаны являются системно-активными антагонистами 5НТили нейрональных никотиновых рецепторов и полезны при ингибировании развития или облегчении состояний, являющихся результатом нарушений серотонинергической или никотинергической трансмиссии, что обеспечивает им широкий диапазон применимости при лечении CNS-нарушений, фармацевтические композиции для указанных целей и способы их получения, а также способ лечения состояний, которые облегчают применением антагониста 5НТили нейрональных никотиновых рецепторов.Отчет о международном поиске был опубликован 2002.04.25.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59710200A | 2000-06-20 | 2000-06-20 | |
PCT/EP2001/006964 WO2001098253A2 (en) | 2000-06-20 | 2001-06-19 | 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200300040A1 true EA200300040A1 (ru) | 2003-06-26 |
EA006067B1 EA006067B1 (ru) | 2005-08-25 |
Family
ID=24390098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200300040A EA006067B1 (ru) | 2000-06-20 | 2001-06-19 | Применение антагонистов 5-ht3 и нейрональных никотиновых рецепторов для лечения различных состояний |
Country Status (21)
Country | Link |
---|---|
US (2) | US20070105961A1 (ru) |
EP (2) | EP1303477A2 (ru) |
JP (1) | JP4159351B2 (ru) |
KR (1) | KR100570374B1 (ru) |
CN (1) | CN1307147C (ru) |
AR (1) | AR032756A1 (ru) |
AU (2) | AU8186101A (ru) |
CA (1) | CA2410852C (ru) |
CZ (1) | CZ2003497A3 (ru) |
EA (1) | EA006067B1 (ru) |
GE (1) | GEP20053431B (ru) |
HK (1) | HK1076276A1 (ru) |
HU (1) | HUP0301551A3 (ru) |
IL (2) | IL153480A0 (ru) |
MX (1) | MXPA02012244A (ru) |
NO (1) | NO329491B1 (ru) |
PL (1) | PL359583A1 (ru) |
TW (1) | TW593223B (ru) |
UA (1) | UA74194C2 (ru) |
WO (1) | WO2001098253A2 (ru) |
ZA (1) | ZA200104187B (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
TW200306189A (en) * | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
AU2003274353B2 (en) * | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
CA2528622C (en) | 2003-05-27 | 2010-08-03 | Forest Laboratories, Inc. | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
US20070082956A1 (en) * | 2003-07-28 | 2007-04-12 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity. |
AR046314A1 (es) * | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
CN101389315A (zh) * | 2004-06-17 | 2009-03-18 | 莫茨药物股份两合公司 | 美金刚口服剂型即释制剂 |
JP2008527035A (ja) * | 2005-01-18 | 2008-07-24 | ユニヴァーシテイ オブ フロリダ | 疼痛を抑制するための組成物及び方法 |
DK2540297T3 (en) | 2008-11-19 | 2015-07-13 | Forum Pharmaceuticals Inc | The treatment of cognitive disorders with (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
US8399519B2 (en) | 2008-12-19 | 2013-03-19 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
TWI432188B (zh) * | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類 |
CR20170556A (es) | 2010-05-17 | 2018-02-27 | Forum Pharmaceuticals Inc | UNA FORMA CRISTALINA DE CLORHIDRATO DE (R)-7-CLORO-N-(QUINUCLIDIN-3-IL) BENZO[B] TIOFENO-2-CARBOXAMIDA MONOHIDRATO (Divisional 2012-0585) |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9411955D0 (en) * | 1994-06-15 | 1994-08-03 | Merck Sharp & Dohme | Therapeutic agents |
US5886051A (en) * | 1995-11-08 | 1999-03-23 | University Of Florida Research Foundation, Inc. | Methods and compositions for the treatment of neurodegeneration |
ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
US6436946B1 (en) * | 1997-05-02 | 2002-08-20 | Morris A. Mann | Xanthine-containing compositions for oral administration and uses related thereto |
US5866585A (en) * | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
PT1009732E (pt) | 1997-06-30 | 2003-10-31 | Merz & Co Gmbh & Co | 1-amino-alquilciclo-hexanos antagonistas do receptor nmda |
US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
AR016212A1 (es) * | 1998-04-28 | 2001-06-20 | Astra Ab | Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas |
US6139861A (en) * | 1999-01-14 | 2000-10-31 | Friedman; Mark | Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm |
US6828462B2 (en) * | 2001-11-07 | 2004-12-07 | Merz Pharma Gmbh & Co. Kgaa | Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
-
2001
- 2001-05-14 TW TW090111488A patent/TW593223B/zh not_active IP Right Cessation
- 2001-05-22 ZA ZA200104187A patent/ZA200104187B/xx unknown
- 2001-06-19 GE GE5059A patent/GEP20053431B/en unknown
- 2001-06-19 JP JP2002504209A patent/JP4159351B2/ja not_active Expired - Fee Related
- 2001-06-19 AU AU8186101A patent/AU8186101A/xx active Pending
- 2001-06-19 KR KR1020027017329A patent/KR100570374B1/ko not_active IP Right Cessation
- 2001-06-19 EP EP01960342A patent/EP1303477A2/en not_active Withdrawn
- 2001-06-19 CN CNB01811413XA patent/CN1307147C/zh not_active Expired - Fee Related
- 2001-06-19 HU HU0301551A patent/HUP0301551A3/hu unknown
- 2001-06-19 AR ARP010102918A patent/AR032756A1/es unknown
- 2001-06-19 EA EA200300040A patent/EA006067B1/ru not_active IP Right Cessation
- 2001-06-19 EP EP10184507A patent/EP2277850A1/en not_active Withdrawn
- 2001-06-19 PL PL01359583A patent/PL359583A1/xx not_active Application Discontinuation
- 2001-06-19 UA UA2003010457A patent/UA74194C2/ru unknown
- 2001-06-19 CA CA002410852A patent/CA2410852C/en not_active Expired - Fee Related
- 2001-06-19 MX MXPA02012244A patent/MXPA02012244A/es active IP Right Grant
- 2001-06-19 AU AU2001281861A patent/AU2001281861B2/en not_active Ceased
- 2001-06-19 WO PCT/EP2001/006964 patent/WO2001098253A2/en active IP Right Grant
- 2001-06-19 CZ CZ2003497A patent/CZ2003497A3/cs unknown
- 2001-06-19 IL IL15348001A patent/IL153480A0/xx active IP Right Grant
-
2002
- 2002-12-16 IL IL153480A patent/IL153480A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026103A patent/NO329491B1/no not_active IP Right Cessation
-
2005
- 2005-09-22 HK HK05108300A patent/HK1076276A1/xx not_active IP Right Cessation
-
2006
- 2006-12-21 US US11/643,129 patent/US20070105961A1/en not_active Abandoned
-
2010
- 2010-07-26 US US12/804,610 patent/US20100298442A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20030053475A (ko) | 2003-06-28 |
CA2410852C (en) | 2007-04-24 |
NO20026103D0 (no) | 2002-12-19 |
AU2001281861B2 (en) | 2006-08-17 |
HK1076276A1 (en) | 2006-01-13 |
HUP0301551A3 (en) | 2005-04-28 |
CN1307147C (zh) | 2007-03-28 |
TW593223B (en) | 2004-06-21 |
PL359583A1 (en) | 2004-08-23 |
CN1620419A (zh) | 2005-05-25 |
US20100298442A1 (en) | 2010-11-25 |
NO20026103L (no) | 2003-02-19 |
EP1303477A2 (en) | 2003-04-23 |
CA2410852A1 (en) | 2001-12-27 |
GEP20053431B (en) | 2005-01-25 |
IL153480A (en) | 2007-08-19 |
MXPA02012244A (es) | 2004-09-06 |
ZA200104187B (en) | 2002-11-22 |
JP2004501130A (ja) | 2004-01-15 |
KR100570374B1 (ko) | 2006-04-24 |
EA006067B1 (ru) | 2005-08-25 |
HUP0301551A2 (hu) | 2003-11-28 |
CZ2003497A3 (cs) | 2004-08-18 |
AU8186101A (en) | 2002-01-02 |
AR032756A1 (es) | 2003-11-26 |
IL153480A0 (en) | 2003-07-06 |
UA74194C2 (ru) | 2005-11-15 |
WO2001098253A3 (en) | 2002-04-25 |
WO2001098253A2 (en) | 2001-12-27 |
US20070105961A1 (en) | 2007-05-10 |
JP4159351B2 (ja) | 2008-10-01 |
NO329491B1 (no) | 2010-10-25 |
EP2277850A1 (en) | 2011-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300040A1 (ru) | 1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторов | |
ATE515513T1 (de) | Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten | |
ATE403437T1 (de) | Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis | |
UA74419C2 (ru) | Замещенные пиридины и их применение как антагонистов рецептора метаботропного глутамата | |
ATE328605T1 (de) | Verwendung von insulin zur behandlung von knorpelkrankheiten | |
DE60022050T2 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
RS20050199A (en) | Imidazolopyridines and methods of making and using the same | |
ATE539768T1 (de) | Kombinationen von metabotropische-glutamat- rezeptor-antagonisten und ihre verwendung zur behandlung von suchtstörungen | |
EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
HK1069339A1 (en) | Substituted diketopiperazines as oxytocin antagonists | |
DE69720745D1 (de) | Therapeutische kombinationen von rar-antagonisten und rxr-agonisten | |
ATE315390T1 (de) | Zyklische polyamine zur behandlung der thrombozytopenie | |
EA200500173A1 (ru) | Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов | |
DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
EA200500803A1 (ru) | Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний | |
ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
EA200400637A1 (ru) | Насыщенные 1-аминоалкилциклогексановые антагонисты nmda, 5-ht3 и нейронных никотиновых рецепторов | |
PT1000046E (pt) | Derivados de piperazina activos no trato urinario inferior | |
WO2005016327A3 (en) | Treatment of sleep disorders with cholinesterase inhibitors | |
MXPA02011921A (es) | Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona. | |
NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists | |
EA200401230A1 (ru) | Азабициклические, азатрициклические и азаспироциклические производные аминоциклогексана в качестве антагонистов рецепторов nmda, 5ht и нейронных никотиновых рецепторов | |
EA200300537A1 (ru) | Антагонисты гистаминовых рецепторов | |
MXPA05007846A (es) | Derivados de diazepanes utiles como inhibidores de lfa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |